Tonix Pharmaceuticals Secures Second Commercial Payer Agreement for TONMYA®, Expanding Total Commercial Coverage to ~52 Million U.S. Lives
Tonix Pharmaceuticals secured a second commercial payer agreement with a leading group purchasing organization (GPO), effective June 1, 2026. This agreement adds approximately 17 million U.S. commercial lives to TONMYA’s coverage, bringing total commercial coverage to ~52 million lives, or 29% of the U.S. commercial market.
Key figures
- Medicaid lives covered
- 75 million
- Us fibromyalgia patients
- 10 million
- Total us commercial lives
- 177 million
- Additional lives from new gpo
- 17 million
- Commercial lives market share
- 29%
- Total commercial lives covered
- 52 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.